-
-
-
-
-
-
-
NeoGenomics integrates oncology testing with Epic health records system
-
-
-
-
-
-
-
NeoGenomics (NEO) Tops Q4 EPS by 2c, provides guidance
-
-
-
-
-
-
-
Piper Sandler Calls Neogenomics (NEO) a 'Compelling, Contrarian Investment Opportunity'
-
-
-
-
-
-
-
BTIG Downgrades Neogenomics (NEO) to Neutral
-
-
-
-
-
-
-
NeoGenomics (NEO) Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight on Neogenomics (NEO) Amid New COO Announcement
-
-
-
-
-
-
-
Neogenomics (NEO) PT Lowered to $17 at Morgan Stanley
-
416,806 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

